AstraZeneca’s new psychedelic fails depression trial

AstraZeneca's experimental psychedelic, an orally administered compound called AZD0328, didn't hit its primary endpoints in a Phase 2a trial for treatment-resistant depression. The study was looking for improvements in patients' depressive symptoms after six weeks. This setback for the biotech giant means its push into psychedelic treatments will likely shift focus.